Citius Pharmaceuticals (CTXR) Current Assets (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Current Assets came in at $31.7 million in Q1 2026, up 72.44% YoY from $18.4 million in Q1 2025, and down 16.5% on a QoQ basis from $37.9 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Current Assets (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 16 years of Current Assets data on file, last reported at $31.7 million in Q1 2026.
- Quarterly Current Assets rose 72.44% year-over-year to $31.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.7 million (up 72.44% YoY) and the FY2025 annual result came in at $27.9 million, up 96.44% from the prior year.
- Current Assets slipped to $31.7 million in Q1 2026, from $37.9 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $58.3 million in Q1 2022 to a low of $14.2 million in Q3 2024.
- A 5-year average of $32.8 million and a median of $31.7 million in 2026 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets sank 58.63% — and 2025, when it soared 107.04%.
- Tracing CTXR's Current Assets over 5 years: stood at $42.3 million in 2022, then sank by 33.34% to $28.2 million in 2023, then plunged by 35.03% to $18.3 million in 2024, then soared by 107.04% to $37.9 million in 2025, then slipped by 16.5% to $31.7 million in 2026.
- The last three Current Assets figures came in at $31.7 million (Q1 2026), $37.9 million (Q4 2025), and $27.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | 43.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.69 Mn |
| Dec 31, 2025 | 37.95 Mn |
| Sep 30, 2025 | 27.93 Mn |
| Jun 30, 2025 | 24.61 Mn |
| Mar 31, 2025 | 18.37 Mn |
| Dec 31, 2024 | 18.33 Mn |
| Sep 30, 2024 | 14.22 Mn |
| Jun 30, 2024 | 28.01 Mn |
| Mar 31, 2024 | 21.57 Mn |
| Dec 31, 2023 | 28.21 Mn |
| Sep 30, 2023 | 34.37 Mn |
| Jun 30, 2023 | 41.11 Mn |
| Mar 31, 2023 | 34.90 Mn |
| Dec 31, 2022 | 42.32 Mn |
| Sep 30, 2022 | 44.56 Mn |
| Jun 30, 2022 | 50.83 Mn |
| Mar 31, 2022 | 58.26 Mn |
| Dec 31, 2021 | 67.94 Mn |
| Sep 30, 2021 | 72.81 Mn |
| Jun 30, 2021 | 116.94 Mn |